文献速递慢性肾脏病肾血管病与高血压

高磷血症通过甘露糖苷酶介导的SCAP N-聚糖复合型转化加剧CKD动脉粥样硬化

Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans.
PubMed 文献 · Kidney Int · 2021-02-23

本文探讨高磷血症加速慢性肾脏病(CKD)动脉粥样硬化的分子机制。研究结合CKD患者、高磷ApoE敲除小鼠及培养血管平滑肌细胞,发现高磷通过上调α-甘露糖苷酶活性促进SCAP N-聚糖复合型转化,延迟SCAP降解,激活SCAP-SREBP2通路,增加细胞内胆固醇合成,从而独立加速动脉粥样硬化。

要点

  • 高磷血症与CKD患者动脉粥样硬化心血管病风险正相关。
  • 高磷通过α-甘露糖苷酶介导SCAP N-聚糖复合型转化,延迟SCAP降解。
  • SCAP蓄积激活SREBP2,上调HMG-CoA还原酶,促进胆固醇合成。

核心结论

  • 高磷血症通过甘露糖苷酶介导的SCAP N-聚糖复合型转化独立加速CKD动脉粥样硬化。

研究设计与样本

  • 研究纳入中国CKD患者、高磷饮食的ApoE敲除小鼠及培养的血管平滑肌细胞。

主要发现

  • 高磷血症与中国CKD患者动脉粥样硬化心血管病风险增加正相关。
  • 高磷血症与ApoE敲除小鼠主动脉严重粥样斑块病变相关。
  • 小鼠动脉SCAP水平升高伴SCAP-SREBP2信号异常激活。
  • 体外过量磷酸盐升高α-甘露糖苷酶活性,促进SCAP N-聚糖复合型转化,延迟SCAP降解。
  • SCAP滞留增强SREBP2反式激活及HMG-CoA还原酶表达,增加细胞内胆固醇合成。

关键数值与推荐

  • ApoE敲除小鼠主动脉及尿毒症伴高磷血症患者桡动脉中α-甘露糖苷酶II活性升高。

临床怎么用

  • 提示管理CKD患者高磷血症可能有助于减轻动脉粥样硬化负担。
  • α-甘露糖苷酶II及SCAP-SREBP2通路可能成为干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blood phosphate levels are linked to atherosclerotic cardiovascular disease in patients with chronic kidney disease (CKD), but the molecular mechanisms remain unclear. Emerging studies indicate an involvement of hyperphosphatemia in CKD accelerated atherogenesis through disturbed cholesterol homeostasis. Here, we investigated a potential atherogenic role of high phosphate concentrations acting through aberrant activation of sterol regulatory element-binding protein (SREBP) and cleavage-activating protein (SCAP)-SREBP2 signaling in patients with CKD, hyperphosphatemic apolipoprotein E (ApoE) knockout mice, and cultured vascular smooth muscle cells. Hyperphosphatemia correlated positively with increased atherosclerotic cardiovascular disease risk in Chinese patients with CKD and severe atheromatous lesions in the aortas of ApoE knockout mice. Mice arteries had elevated SCAP levels with aberrantly activated SCAP-SREBP2 signaling. Excess phosphate in vitro raised the activity of α-mannosidase, resulting in delayed SCAP degradation through promoting complex-type conversion of SCAP N-glycans. The retention of SCAP enhanced transactivation of SREBP2 and expression of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, boosting intracellular cholesterol synthesis. Elevated α-mannosidase II activity was also observed in the aortas of ApoE knockout mice and the radial arteries of patients with uremia and hyperphosphatemia. High phosphate concentration in vitro elevated α-mannosidase II activity in the Golgi, enhanced complex-type conversion of SCAP N-glycans, thereby upregulating intracellular cholesterol synthesis. Thus, our studies explain how hyperphosphatemia independently accelerates atherosclerosis in CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhou C, He Q, Gan H, et al. Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans. Kidney Int. 2021. PMID: 33631226. doi:10.1016/j.kint.2021.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。